CoChat

Paroxetine in the Treatment of Generalized Social Phobia: Open-Label Treatment and Double-Blind Placebo-Controlled Discontinuation

Stein, Murray B., Chartier, Mariette J., Hazen, Andrea L., Kroft, Cara D.L., Chale, Ron A., Cote, Dennis, Walker, John R. · 1996 · Journal of Clinical Psychopharmacology
Cited by 134

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

We conducted an 11-week forced-escalation open-label study of paroxetine in the treatment of 36 patients with generalized social phobia. At the mean dosage of 47.9 +/- 6.2 mg/day, 23 of 30 completers (77%) were deemed responders on the basis of a clinician rating of either "very much improved" or "much improved" on the Clinical Global Impressions scale. Duke Social Phobia Scale ratings declined from 35.5 +/- 13.1 at baseline to 19.7 +/- 17.4 at week 11 (p < 0.0005), and Liebowitz Social Anxiety Scale ratings declined from 75.1 +/- 25.4 at baseline to 37.2 +/- 32.5 at week 11 (p < 0.0005). Sixteen responders were randomized to an additional 12 weeks of either paroxetine (with no dosage change) or placebo (after a taper period) on a double-blind basis. To the best of our knowledge, this is the first controlled medication-discontinuation study in social phobia. One of eight patients randomized to continue paroxetine relapsed versus five of eight patients randomized to placebo. These findings call for a double-blind, placebo-controlled treatment study of paroxetine in generalized social phobia. They also suggest that relapse rates are high if medication is discontinued early and that further study is needed to determine (1) the optimal duration of maintenance pharmacotherapy for social phobia and (2) if specific psychotherapeutic interventions before medication discontinuation may prevent relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-199606000-00005

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 21

  1. Kessler, 1994, Arch Gen Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  2. Stein, 1994, Am J Psychiatry, 151, 408, 10.1176/ajp.151.3.408 · DOI · Paper page
  3. Davidson, 1994, Arch Gen Psychiatry, 51, 975, 10.1001/archpsyc.1994.03950120047008 · DOI · Paper page
  4. Schneier, 1994, J Clin Psychiatry, 55, 322
  5. Versiani, 1992, Br J Psychiatry, 161, 353, 10.1192/bjp.161.3.353 · DOI · Paper page
  6. van Vliet, 1992, Eur Neuropsychopharmacol, 2, 21, 10.1016/0924-977X(92)90032-4 · DOI
  7. Davidson, 1993, J Clin Psychopharmacol, 13, 423, 10.1097/00004714-199312000-00008 · DOI · Paper page
  8. Hovens, 1994, J Am Acad Child Adolesc Psychiatry, 33, 476, 10.1097/00004583-199405000-00005 · DOI · Paper page
  9. Lotufo-Neto, 1994, Addiction, 89, 447, 10.1111/j.1360-0443.1994.tb00925.x · DOI
  10. van Ameringen, 1993, J Clin Psychiatry, 54, 27
  11. Black, 1992, J Clin Psychopharmacol, 12, 293, 10.1097/00004714-199208000-00022 · DOI · Paper page
  12. Schneier, 1992, J Clin Psychopharmacol, 12, 62, 10.1097/00004714-199202000-00018 · DOI · Paper page
  13. van Ameringen, 1994, J Affect Disord, 31, 141, 10.1016/0165-0327(94)90118-X · DOI
  14. van Vliet, 1994, Psychopharmacology, 115, 128, 10.1007/BF02244762 · DOI · Paper page
  15. Katzelnick, 1995, Am J Psychiatry, 152, 1368, 10.1176/ajp.152.9.1368 · DOI · Paper page
  16. Gelernter, 1992, J Clin Psychiatry, 53, 23
  17. Heimberg, 1990, J Nerv Ment Dis, 178, 172, 10.1097/00005053-199003000-00004 · DOI · Paper page
  18. Heimberg, 1993, J Anxiety Disord, 7, 249, 10.1016/0887-6185(93)90006-7 · DOI · Paper page
  19. Mannuzza, 1995, Arch Gen Psychiatry, 52, 230, 10.1001/archpsyc.1995.03950150062011 · DOI · Paper page
  20. Watson, 1969, J Consult Clin Psychol, 33, 448, 10.1037/h0027806 · DOI · Paper page
  21. Mattick, 1989, Behav Ther, 20, 3, 10.1016/S0005-7894(89)80115-7 · DOI · Paper page

Cited by

See all 134

Metadata

Authors
Stein, M. B., Chartier, M. J., Hazen, A. L., Kroft, C. D. L., Chale, R. A., Cote, D., & Walker, J. R.
Venue
Journal of Clinical Psychopharmacology
Published
1996-06
Volume
16
Issue
3
Pages
218-222
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2313023493
Cited by
134
References
8
FWCI
22.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Paroxetine in the Treatment of Generalized Social Phobia: Open-Label Treatment and Double-Blind Placebo-Controlled Discontinuation. https://app.cochat.ai/papers/10.1097/00004714-199606000-00005
The paper
Stein, M. B., Chartier, M. J., Hazen, A. L., Kroft, C. D. L., Chale, R. A., Cote, D., & Walker, J. R. (1996). Paroxetine in the Treatment of Generalized Social Phobia: Open-Label Treatment and Double-Blind Placebo-Controlled Discontinuation. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199606000-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.